Heather N Reich

List of Publications by Year
in descending order

86 papers	5,821 citations	94269 37 h-index	79541 73 g-index
87 all docs	87 docs citations	87 times ranked	5250 citing authors

#	Article	IF	Citations
1	Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte Î²3 Integrin. Kidney International Reports, 2022, 7, 68-77.	0.4	10
2	How Should Pathology Findings Influence Treatment in IgA Nephropathy?. Kidney International Reports, 2022, 7, 3-5.	0.4	3
3	Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses. JCI Insight, 2022, 7, .	2.3	13
4	The Canadian Glomerulonephritis Registry (CGNR) and Translational Research Initiative: Rationale and Clinical Research Protocol. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210890.	0.6	1
5	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney International, 2022, 102, 160-172.	2.6	25
6	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2022, 327, 1888.	3.8	103
7	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. Journal of Rheumatology, 2021, 48, 555-566.	1.0	27
8	Evaluation of the Pharmacokinetics and Exposureâ€“Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 2021, 60, 517-525.	1.6	6
9	Corticosteroids Should Be Used To Treat Slowly Progressive IgA Nephropathy: PRO. Kidney360, 2021, 2, 1078-1080.	0.9	1
10	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	0.9	3
11	Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants. Kidney Medicine, 2021, 3, 257-266.	1.0	9
12	Interpretation and Clinical Value of Serum Anti-PLA2R-Antibody Testing. journal of applied laboratory medicine, The, 2021, 6, 799-803.	0.6	0
13	IgA Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 2021, 78, 429-441.	2.1	96
14	Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 9513.	1.8	9
15	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	2.6	325
16	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 436-447.	3.0	34
17	The microbiome and IgA nephropathy. Seminars in Immunopathology, 2021, 43, 649-656.	2.8	12
18	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 2021, 52, 827-836.	1.4	15

#	Article	IF	Citations
19	P0350THE DURATION OF PROTEINURIA REMISSION AND CLINICAL OUTCOMES IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
20	The Authors Reply. Kidney International Reports, 2020, 5, 1612-1613.	0.4	0
21	Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney International Reports, 2020, 5, 2032-2041.	0.4	84
22	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	1.4	14
23	Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy. Kidney International Reports, 2020, 5, 706-717.	0.4	8
24	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 582-593.	5.5	155
25	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney International, 2020, 98, 1009-1019.	2.6	35
26	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	13.9	324
27	Rethinking Lupus Nephritis Classification on a Molecular Level. Journal of Clinical Medicine, 2019, 8, 1524.	1.0	21
28	Renal SGLT mRNA expression in human health and disease: a study in two cohorts. American Journal of Physiology - Renal Physiology, 2019, 317, F1224-F1230.	1.3	18
29	Disease-specific incident glomerulonephritis displays geographic clustering in under-servicedÂrural areas of British Columbia,ÂCanada. Kidney International, 2019, 96, 421-428.	2.6	14
30	Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine, 2019, 179, 942.	2.6	266
31	The Case | Severe symptomatic hypocalcemia in aÂpatient with sickle cell disease. Kidney International, 2019, 96, 1429-1430.	2.6	0
32	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	2.1	68
33	What Is Really in This Weight Loss Supplement?. journal of applied laboratory medicine, The, 2019, 4, 270-273.	0.6	1
34	An update on predicting renal progression in IgA nephropathy. Current Opinion in Nephrology and Hypertension, 2018, 27, 214-220.	1.0	42
35	Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811774953.	0.6	38
36	IgA Vasculitis in Adults. Current Treatment Options in Rheumatology, 2018, 4, 119-132.	0.6	3

#	Article	IF	Citations
37	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. American Journal of Physiology - Renal Physiology, 2018, 314, F412-F422.	1.3	68
38	Closer to the Source: Targeted-Release Corticosteroids for Immunoglobulin A Nephropathy. American Journal of Kidney Diseases, 2018, 71, 6-8.	2.1	0
39	Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. PLoS ONE, 2018, 13, e0196117.	1.1	40
40	Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2018, 314, F667-F674.	1.3	41
41	Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes. Journal of Pediatrics, 2018, 198, 247-253.e1.	0.9	14
42	IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 677-686.	2.2	358
43	Influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F599-F606.	1.3	22
44	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F335-F342.	1.3	33
45	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	1.3	46
46	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. Diabetologia, 2017, 60, 581-584.	2.9	65
47	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 432.	3.8	376
48	Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes. Cytokine, 2017, 99, 233-239.	1.4	27
49	Nephrotic Syndrome With Cancer Immunotherapies: AÂReportÂofÂ2 Cases. American Journal of Kidney Diseases, 2017, 70, 581-585.	2.1	76
50	Is there a role for immunosuppression in immunoglobulin A nephropathy?. Nephrology Dialysis Transplantation, 2017, 32, i30-i36.	0.4	7
51	Membranous Nephropathy: Quantifying Remission Duration on Outcome. Journal of the American Society of Nephrology: JASN, 2017, 28, 995-1003.	3.0	53
52	A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Research and Therapy, 2016, 18, 218.	1.6	27
53	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	2.6	51
54	Early changes in cardiovascular structure and function in adolescents with type 1 diabetes. Cardiovascular Diabetology, 2016, 15, 31.	2.7	64

#	Article	IF	Citations
55	Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney International, 2016, 89, 1111-1118.	2.6	55
56	Association Between Plasma Uric Acid Levels and Cardiorenal Function in Adolescents With Type 1 Diabetes. Diabetes Care, 2016, 39, 611-616.	4.3	22
57	The urinary inflammatory profile in gluten free dietâ€"adherent adolescents with type 1 diabetes and celiac disease. Journal of Diabetes and Its Complications, 2016, 30, 295-299.	1.2	6
58	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. Journal of Rheumatology, 2016, 43, 97-120.	1.0	66
59	The MEST score provides earlier risk prediction in lgA nephropathy. Kidney International, 2016, 89, 167-175.	2.6	190
60	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	0.8	14
61	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides â€“ Executive Summary. Canadian Journal of Kidney Health and Disease, 2015, 2, 78.	0.6	12
62	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology, 2015, 54, 449-457.	0.9	37
63	Matching Kidneys and Urines: Establishing Noninvasive Surrogates of Intrarenal Events in Primary Glomerulonephritis. Seminars in Nephrology, 2015, 35, 256-265.	0.6	1
64	Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney International, 2015, 88, 1392-1401.	2.6	37
65	The Molecular Phenotype of Endocapillary Proliferation: Novel Therapeutic Targets for IgA Nephropathy. PLoS ONE, 2014, 9, e103413.	1.1	30
66	The Urinary Cytokine/Chemokine Signature of Renal Hyperfiltration in Adolescents with Type 1 Diabetes. PLoS ONE, 2014, 9, e111131.	1.1	18
67	A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P.) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Transplantation, 2014, 29, 1570-1577.	0.4	92
68	Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney International, 2014, 85, 1412-1420.	2.6	76
69	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults. American Journal of Kidney Diseases, 2014, 63, 363-377.	2.1	28
70	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in Children. American Journal of Kidney Diseases, 2014, 63, 354-362.	2.1	42
71	The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. CKJ: Clinical Kidney Journal, 2014, 7, 538-545.	1.4	15
72	An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework. BMC Nephrology, 2013, 14, 236.	0.8	27

#	Article	IF	Citations
73	Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney International, 2013, 84, 1017-1024.	2.6	106
74	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	2.6	268
75	Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 303, R710-R718.	0.9	60
76	The Effect of Direct Renin Inhibition Alone and in Combination With ACE Inhibition on Endothelial Function, Arterial Stiffness, and Renal Function in Type 1 Diabetes. Diabetes Care, 2012, 35, 2324-2330.	4.3	44
77	Risk Stratification of Patients With IgA Nephropathy. American Journal of Kidney Diseases, 2012, 59, 865-873.	2.1	137
78	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney International, 2011, 79, 914-920.	2.6	60
79	Validation of the Oxford classification of IgA nephropathy. Kidney International, 2011, 80, 310-317.	2.6	164
80	A Molecular Signature of Proteinuria in Glomerulonephritis. PLoS ONE, 2010, 5, e13451.	1.1	78
81	Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes. Diabetes Care, 2010, 33, 361-365.	4.3	84
82	The impact of sex in primary glomerulonephritis. Nephrology Dialysis Transplantation, 2008, 23, 2247-2253.	0.4	108
83	Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney International, 2008, 74, 1610-1616.	2.6	209
84	Remission of Proteinuria Improves Prognosis in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 3177-3183.	3.0	471
85	Albumin Activates ERKViaEGF Receptor in Human Renal Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 1266-1278.	3.0	78
86	Interactions between gender and the angiotensin type 1 receptor gene polymorphism. Kidney International, 2003, 63, 1443-1449.	2.6	34